Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study

Autor: J Jansen, L J T Smits, R W M Pauwels, W Kievit, D J de Jong, A C de Vries, F Hoentjen, C J van der Woude, A.A. van Bodegraven, A.G.L. Bodelier, P.J. Boekema, N. de Boer, P.C.J. ter Borg, A.A. den Broeder, I.A.M Gisbertz, F.M Jansen, S.V. Jansen, D.J. de Jong, W. Kievit, R.C.A. van Linschoten, M Löwenberg, M.W.M.D. Lutgens, R.C. Mallant-Hent, A.E. van der Meulen, B. Oldenburg, R.W.M. Pauwels, M Pierik, M.J.L. Romberg-Camps, T.E.H. Römkens, M.G.V.M. Russel, L.J.T. Smits, A.C.I.T.L. Tan, M.L. Verhulst, A.C. de Vries, R.L. West, F.H.J. Wolfhagen, C.J. van der Woude

Publikováno v: BMJ Open, Vol 10, Iss 5 (2020)

Introduction Adalimumab is effective for maintenance of remission in patients with Crohn’s disease (CD) at a dose of 40 mg subcutaneously every 2 weeks. However, adalimumab is associated with (long-term) adverse events and is costly. The aim of thi

Externí odkaz: https://doaj.org/article/137bae053ba5412d9dec48e602f720d7

Saliva oxytocin, cortisol, and testosterone levels in adolescent boys with autism spectrum disorder, oppositional defiant disorder/conduct disorder and typically developing individuals

Autor: Anne F.M. Jansen, Corina U. Greven, Floor Scheepers, M.J. Bakker-Huvenaars, Evita C Wiegers, R. van der Steen, Jan K. Buitelaar, A.E. van Herwaarden, Pierre C. M. Herpers, Nanda Rommelse, Jeffrey C. Glennon, A.N. Baanders, Karin S. Nijhof

Publikováno v: European Neuropsychopharmacology, 30, pp. 87-101
European Neuropsychopharmacology, 30, 87-101

Contains fulltext : 214790.pdf (Publisher’s version ) (Closed access) The aim of the current study was to compare levels of oxytocin, cortisol, and testosterone in adolescents with either autism spectrum disorder (ASD), or oppositional defiant diso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::182c10100cc36fd03fa09310e39957ca
https://doi.org/10.1016/j.euroneuro.2018.07.097

Multi-omics Examination of Q Fever Fatigue Syndrome Identifies Similarities with Chronic Fatigue Syndrome

Autor: Chantal P. Bleeker-Rovers, Leo A. B. Joosten, Cheng-Jian Xu, Mihai G. Netea, Yang Li, Megan E. Roerink, Anne F.M. Jansen, Jos W. M. van der Meer, Ranko Gacesa, Stephan P. Keijmel, Ruud P. H. Raijmakers

Publikováno v: Journal of Translational Medicine
Journal of Translational Medicine, 18
Journal of translational medicine
England
Journal of translational medicine, 18(1):448, 1-13. BioMed Central Ltd.
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-13 (2020)
Journal of Translational Medicine, 18, 1

Background Q fever fatigue syndrome (QFS) is characterised by a state of prolonged fatigue that is seen in 20% of acute Q fever infections and has major health-related consequences. The molecular mechanisms underlying QFS are largely unclear. In orde

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::403944b0ef3e2bb5334a91e52fd18131
https://doi.org/10.21203/rs.3.rs-54097/v1

Autoimmunity and B-cell dyscrasia in acute and chronic Q fever: A review of the literature

Autor: Ruud P. H. Raijmakers, Chantal P. Bleeker-Rovers, Anne F.M. Jansen, Marcel van Deuren, Stephan P. Keijmel, Jos W. M. van der Meer, Renate G. van der Molen, Gerald Vervoort

Publikováno v: European Journal of Internal Medicine, 54, pp. 6-12
European Journal of Internal Medicine, 54, 6-12

Q fever infection can lead to chronic Q fever, a potentially lethal disease occurring in 1-5% of patients infected with Coxiella burnetii, characterized by the persistence of this intracellular bacterium. It usually presents as endocarditis, infected

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d625f5927b6f4a10406d929ac9f2a10
https://doi.org/10.1016/j.ejim.2018.06.007

Ataxia-telangiectasia: Immunodeficiency and survival

Autor: Marcel van Deuren, Ásgeir Haraldsson, Corry M.R. Weemaes, Amit Rawat, Anne F.M. Jansen, Nienke J H van Os, Nel Roeleveld, Tomohiro Morio, M.H.D. Schoenaker, Michèl A.A.P. Willemsen, Michiel van der Flier, Nieke T.M. van Driel, Bart P.C. van de Warrenburg, Alex M. Taylor, Charlotte A. Haaxma, Annarosa Soresina, Amos Etzioni

Publikováno v: Clinical Immunology, 178, 45-55
Clinical Immunology, 178, pp. 45-55

Contains fulltext : 174098.pdf (Publisher’s version ) (Open Access) Ataxia-telangiectasia (AT) is a neurodegenerative disorder characterized by ataxia, telangiectasia, and immunodeficiency. An increased risk of malignancies and respiratory diseases

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a5525d4f7a4014b8ebe7604f6cff368
https://doi.org/10.1016/j.clim.2017.01.009